Price
No data yet.
Social Signal Score
Revenue
$15.48B+99.55%Company Profile
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- Beta
- 0.66
- Country
- US
Financials
Revenue
$15.48B+99.6%Net Income
$1.00B+413.6%EBITDA
$1.51B+191.5%Free Cash Flow
$-817.00M-361.4%EPS (diluted)
$3.03+621.4%Shares Outstanding (diluted)
330.20M-28.5%Operating Expenses
$2.74BCash & Debt
$9.41BReturn of Capital
$164.00MDividend per Share
$0.50Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2017 | $60.53B | $1.90B | $9.16 |
| 2016 | $63.16B | $2.27B | $6.41 |
| 2015 | $60.34B | $2.39B | $6.84 |
| 2014 | $58.00B | $2.04B | $5.74 |
| 2013 | $47.29B | $1.91B | $5.38 |
| 2012 | $36.60B | $1.66B | $4.87 |
| 2011 | $33.78B | $1.99B | $5.22 |
| 2010 | $34.25B | $1.77B | $4.25 |
| 2009 | $34.76B | $1.28B | $2.96 |
| 2008 | $30.95B | $1.38B | $3.00 |
| 2007 | $27.60B | $1.83B | $3.60 |
| 2006 | $25.15B | $1.70B | $3.12 |
| 2005 | $22.49B | $1.63B | $2.82 |
| 2004 | $19.90B | $2.25B | $3.71 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AET's reported EPS growth of 7.2% a year over 13 years.
- EPS in 5 years
- $8.25
- Implied price
- $82.48
- Return from $106.35
- -5.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $41.01 — -61.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 6 | 8 | 10 | 12 | 14 |
|---|---|---|---|---|---|
| -2.8% | -22.2% | -17.6% | -13.8% | -10.6% | -7.8% |
| 2.2% | -18.2% | -13.3% | -9.4% | -6.0% | -3.1% |
| 7.2% | -14.2% | -9.1% | -5.0% | -1.4% | 1.7% |
| 12.2% | -10.2% | -4.9% | -0.5% | 3.2% | 6.4% |
| 17.2% | -6.2% | -0.6% | 3.9% | 7.8% | 11.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+0.00%Social Signal Score
Mentions (5)
- Newsprnewswire.com·14d ago·Positive
Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience HARTFORD, Conn., Oct 8, 2026 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), announced today that more than 69 percent of its Medicare Advantage (MA) members are in 2027 plans rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS).
View source ↗ - Newsprnewswire.com·20d ago·Negative
Aetna 2027 Medicare plans offer reliable, affordable access to care & member support Plans designed to provide member value and access to care: $0 copays on Tier 1 drugs and covered vaccines at in-network pharmacies* $0 copays for annual physicals, colonoscopies and mammograms at in-network providers $0 copays for annual Healthy Home Visit from a licensed Signify Health clinician Dental, vision and hearing benefits A continued focus on affordability, quality care and preserving the benefits that
View source ↗ - Newsreuters.com·36d ago·Neutral
CVS Health's Aetna to streamline cancer treatment approvals CVS Health's Aetna health insurance unit will cut back next year on the preapprovals it requires for treatment for cancer patients to only one medical prior authorization process early on, the company said on Thursday.
View source ↗ - Newsprnewswire.com·36d ago·Neutral
Aetna expands bundled oncology prior authorizations, easing provider burden and accelerating member access to care Oncology bundling to support all eligible Medicaid members for all cancer types Full roll-out across all Aetna businesses in 2027 HARTFORD, Conn., Sept. 17, 2026 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), is expanding prior authorization bundles across all cancer types for members in eligible1 Medicaid states as of September 1, with plans to expand across all lines o
View source ↗ - Newszacks.com·45d ago·Positive
Here's How CVS Is Focusing on Aetna's Profitability Turnaround CVS Health is advancing Aetna's profitability turnaround, supported by stronger Health Care Benefits results, an improved MBR and operational initiatives.
View source ↗
Insider trading
Open-market buys and sells by AET officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Robert J. Wittmanhouse · VA01 · disclosed Dec 12, 2018 (13d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.